Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma

Dermatologic Surgery

Volumn 32, Issue 1, 2006, Pages 63-69

  Spencer, James M ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Spencer Dermatology and Skin Surgery Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR 7; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; CURETTAGE; DESICCATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTRODESICCATION; ELECTROSURGERY; FEMALE; HUMAN; HYPOPIGMENTATION; MALE; MINIMAL RESIDUAL DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAR; SKIN ATROPHY; WOUND HEALING; ADJUVANT CHEMOTHERAPY; PATHOLOGY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CHEMOTHERAPY, ADJUVANT; DESICCATION; DOUBLE-BLIND METHOD; ELECTROSURGERY; FEMALE; HUMANS; MALE; NEOPLASM, RESIDUAL; PILOT PROJECTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33645802442     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00740.x     Document Type: Article

References (22)

1. American Cancer Society. Cancer facts & gures 2004. Available at accessed Sept 30, 2004
2. Harris RB Grifth K Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001 45 528 36.
3. Hoy WE. Nonmelanoma skin carcinoma in Albuquerque, New Mexico experience of a major health care provider. Cancer 1996 77 2489 95.
4. Marks R Staples M Giles GG. Trends in non-melanocytic skin cancer treated in Australia the second national survey. Int J Cancer 1993 53 585 90.
5. Gallagher RP Ma B McLean DI et al. Trends in basal cell carcinoma, squa-mous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol 1990 23 413 21.
6. Scrivener Y Grosshans E Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002 147 41 7.
7. Walling HW Fosko SW Geraminejad PA et al. Aggressive basal cell carcinoma presentation, pathogenesis, and management. Cancer Metastasis Rev 2004 23 389 402.
8. Silverman MK Kopf AW Grin CM et al. Recurrence rates of treated basal cell carcinomas. Part 2 curettage-electrodesiccation. J Dermatol Surg Oncol 1991 17 20 6.
9. Spencer JM Tannenbaum A Sloan L Amonette RA. Does inammation con-tribute to the eradication of basal cell carcinoma following curettage and elec-trodesiccation? Dermatol Surg 1997 23 625 31.
10. Edens BL Bartlow GA Haghighi P et al. Effectiveness of curettage and elec-trodesiccation in the removal of basal cell carcinoma. J Am Acad Dermatol 1983 9 383 8.
11. Suhge d'Aubermont PC Bennett RG. Failure of curettage and electrodesicca-tion for removal of basal cell carcinoma. Arch Dermatol 1984 120 1456 60.
12. Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 1983 8 496 503.
13. Rowe DE Carroll RJ Day CL Jr.. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma implications for patient followup. J Dermatol Surg Oncol 1989 15 315 28.
14. Baryza MJ Baryza GA. The Vancouver Scar Scale an administration tool and its interrater reliability. J Burn Care Rehabil 1995 16 535 8.
15. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997 276 75 81.
16. Nouri K Spencer JM Taylor JR et al. Does wound healing contribute to the eradication of basal cell carcinoma fol-lowing curettage and electrodessication? Dermatol Surg 1999 25 183 8.
17. De Panfilis G Colli V Manfredi G et al. In situ identication of mononuclear cells infiltratimg cutaneous carcinoma an immuno-histochemical study. Acta Derm Venereol 1979 59 219 22.
18. Kohchiyama A Oka D Ueki H. Expression of human lymphocyte antigen (HLA)-DR on tumor cells in basal cell carcinoma. J Am Acad Dermatol 1987 16 833 8.
19. Weinstein GD Frost P. Cell proliferation in human basal cell carcinoma. Cancer Res 1970 30 724 8.
20. Shanoff LB Spira M Hardy SB. Basal cell carcinoma a statistical approach to rational management. Plast Reconstr Surg 1967 39 619 24.
21. Nedelec B Dodd CM Scott PG et al. Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo. Wound Repair Regen 1998 6 202 12.
22. Tredget EE Shankowsky HA Pannu R et al. Transforming growth factor-beta in thermally injured patients with hyper-trophic scars effects of interferon alpha-2b. Plast Reconstr Surg 1998 102 1317 30.